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Background: The gut microbiota play an essential role in protecting the host against
pathogenic microorganisms by modulating immunity and regulating metabolic processes.
In response to environmental factors, microbes can hugely alter their metabolism. These
factors can substantially impact the host and have potential pathologic implications.
Particularly pathogenic microorganisms colonizing pancreas and biliary tract tissues may
be involved in chronic inﬂammation and cancer evolution.
Purpose: To evaluate the effect of bile microbiota on survival in patients with pancreas and
biliary tract disease (PBD).
Patients and Methods: We investigated 152 Italian patients with cholelithiasis (CHL),
cholangitis (CHA), cholangiocarcinoma (CCA), gallbladder carcinoma (GBC), pancreas
head carcinoma (PHC), ampullary carcinoma (ACA), and chronic pancreatitis (CHP).
Demographics, bile cultures, therapy, and survival rates were analyzed in cohorts (T1 death
<6 months; T2 death <12 months; T3 death <18 months, T3S alive at 18 months).
Results: The most common bacteria in T1 were E. coli, K. pneumoniae, and P. aeruginosa. In
T2, the most common bacteria were E. coli and P. aeruginosa. In T3, there were no signiﬁcant
bacteria isolated, while in T3S the most common bacteria were like those found in T1. E. coli
and K. pneumoniae were positive predictors of survival for PHC and ACA, respectively.
E. coli, K. pneumoniae, and P. aeruginosa showed a high percentage of resistant bacteria to
3CGS, aminoglycosides class, and quinolone group especially at T1 and T2 in cancer patients.
Conclusions: An unprecedented increase of E. coli in bile leads to a decrease in survival.
We suggest that some strains isolated in bile samples may be considered within the group of
risk factors in carcinogenesis and/or progression of hepato-biliary malignancy. A better
understanding of bile microbiota in patients with PBD should lead to a multifaceted approach
to rapidly detect and treat pathogens before patients enter the surgical setting in tandem with
the implementation of the infection control policy.
Keywords: human bile microorganisms, survival, pancreatic and biliary tract disease, E. coli
Introduction
The gut microbiota plays an indispensable role in protecting the host against
pathogenic microorganisms by modulating immunity and regulating metabolic
processes.1 In response to environmental factors, microbes can hugely alter their
metabolism. These factors can substantially impact the host and have potential
pathologic implications. In 1989, Wells published a work in which he demon-
strated that the post-surgical infections were more often to be found in patients
with non-sterile bile.2 Since then, there is increasing interest in the bile micro-
biome of the hepatobiliary system. There is an increasing interest to investigate
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cohorts of patients according to the STROBE guidelines.
STROBE stands for international collaboration of epide-
miologists, methodologists, statisticians, researchers, and
editors involved in the conduct and diffusion of observa-
tional studies, with the common aim of STrengthening
the Reporting of OBservational studies in Epidemiology.3
The importance to target the bile microbiota may suggest
avenues for future studies of biomarkers and therapeutic
interventions in hepatobiliary disease.4–8
The primary malignancies of the biliary tract, ie, cholan-
giocellular carcinoma (CCA) and gallbladder carcinoma
(GBC), have been traditionally diagnosed at an advanced
stage and harbor a low sensitivity to radiation and
chemotherapy.9 In the last decade, both the diagnostic and
therapeutic approaches of these patients have started to
change because of the improvement of imaging and the
introduction of new chemical compounds addressing speciﬁc
signaling pathways of carcinogenesis.9–12 On the other hand,
the mortality in some groups of malignancies of the pancrea-
tic-biliary system remains obscurely high with low survival
rates.13–15 Our research question was to address the potential
clinical impact of the bile microbiota in these patients and if
Enterobacteriaceae are signiﬁcantly associated with neo-
plasms of the pancreas and biliary tract.
Accumulating evidence indicates that a multidisciplinary
approach to surgical and non-surgical treatment strategies for
patients with complex pancreatic and biliary disease is crucial.16
Thus, a series of interdisciplinary meetings occurred in our
institution with occasional foreign visitors with expertise in
clinical pathology and public health. Preoperative biliary drai-
nage (POBD) is often performed by endoscopic placement of an
endo-biliary stent into the common bile duct (CBD) or via
percutaneous transhepatic drainage of the biliary tract or after
decompression of the biliary duct. Previous studies showed
a favorable effect of POBD on postoperative morbidity and
mortality, although a stent may be a signiﬁcant risk factor for
bacterial contamination of the biliary system. Subjects with
microbiota that is resistant to antibiotics are at an increased
risk of postoperative infection as also shown in previous
research work from us and others.17–20 Moreover, oncologic
patientsmay be affected bymalnutrition or cachexia and exhibit
a low quality of life, increased morbidity and mortality, pro-
longed hospital stays, and a reduced response to treatment.21–23
Postoperative complications may also inﬂuence biliary
microbiota.24–26 In line with this research, we hypothesized
that certain kinds of bacterial and/or fungal microorganisms
isolated in bile might be associated with speciﬁc pancreas and
biliary tract diseases (PBDs) especially in surgical patients
undergoing surgery due to PBD. A particular strain might be
responsible for a decrease in survival other than the neoplastic
disease. We retrospectively investigated the microbiota in the
bile of surgical patients with PBD for a correlation between
dead/survived patients considering bacterial strains collected
from the bile, the underlying disease, and the anti-infective
therapy.
Materials and methods
Study design and patients
This study is a single-center cohort investigation that was
performed in a quality assurance (QA)-certiﬁed academic
setting.27 We retrieved the ﬁles of patients with a diagnosis
of cholelithiasis (CHL), cholangitis (CHA), CCA, GBC,
carcinoma of the head of the pancreas (PHC), ampullary
carcinoma (ACA), and chronic pancreatitis (CHP). The
patients were hospitalized at the Department of General
and Emergency Surgery, University Hospital of Palermo,
Italy, between June 2010 and June 2014, with follow-up
until December 2016. The study population consisted of
patients with positive culture of bile samples collected
during endoscopic retrograde cholangiopancreatography
(ERCP) from patients harboring hepatobiliary disease at
an external quality assurance-certiﬁed General Surgery
and Emergency Academic Unit by the same operator
(FD) as previously published.28,29
Routine Antibiotic prophylaxis was not administrated in
unselected patients underwent to ERCP for bile sampling as
reported in the literature (Performance measures for ERCP
and endoscopic ultrasound: a European Society of
Gastrointestinal Endoscopy (ESGE) Quality Improvement
Initiative).30 The operational guidelines for anti-infective
prophylaxis used in the study period were previously
reported31 and also available on the website of the
University Hospital “P. Giaccone” of Palermo, Italy (http://
www. p o l i c l i n i c o . p a . i t / p o r t a l / p d f / n ew s /C IO /
LineeGuidaAntibioticoProﬁlassiLast.pdf)
The patient population included hospitalized patients at
the ﬁrst surgery (58%) and patients readmitted at our unit
(12%). Our surgical emergency reference admitted out-
patients are also coming from several surgical groups
(30%). All outpatients (30%) were emergency cases and
showed a history of surgery. Moreover, half of the patients
had a history of previous antibiotic treatment. The inci-
dence of comorbidities such as diabetes and cardiovascular
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disease mirrored those reported in the general population
according to age and sex during the study period.32
Data about kind of surgical intervention applied at the
Department of General and Emergency Surgery of the
Policlinic of Palermo and experience about revision, re-
exploration, and solution of complications of surgical pro-
cedures performed both in the open and in a laparoscopic
way have previously been reported.33 In general, in reset-
table pancreatic cancer and periampullary neoplasms, pre-
operative biliary drainage was done with ERCP if the
serum bilirubin was more than 20 mg/dl or if the patient
had a fever because of acute CHA.33 In gallstones disease
and acute cholecystitis, a laparoscopic approach was pre-
ferred in elderly patients.34 According to European guide-
lines, a biliary stent was placed in cases of malignant
obstruction and if the tumor was unresectable (about
18% of enrolled patients).
Ethics procedures and adherence to
STROBE guidelines
All the patients gave written informed consent for surgical
procedures and collection and storage of research data set
including their anonymous publication according to ethical
guidelines of the Declaration of Helsinki for clinical studies.
Moreover, a written informed consent, also including the
potential release of the patient’s details, was obtained from
each patient’s next of kin by the principles of the Declaration
of Helsinki as previously reported. Our study was inserted in
the surveillance program for multidrug-resistant Gram-
negative bacilli, including active surveillance cultures, that
has been carried out in the Surgical Emergency Unit since
January 2010 as previously reported.35,36 The study protocol
was fully approved by the Ethics Committee of the Azienda
Ospedaliero-Universitaria Policlinic “P. Giaccone”,
University of Palermo, Palermo, Italy (IRB n.10_8/2013).
This work follows the STROBE guidelines for retrospective
cohort studies.3
The cyto- and/or histopathological examination was
performed in a Quality Assurance (QA)-certiﬁed hospital
only setting using protocols and standard operative
procedures.37
Microbiota identiﬁcation
Bacterial identiﬁcation with antimicrobial susceptibility
testing was carried out by collecting laboratory data
using either the Phoenix Automated Microbiology
System (Becton Dickinson Diagnostic Systems, Sparks,
United States) or the Vitek-2 System (Bio-Mérieux,
Marcy l’Etoile, France).38,39 Antibiotic susceptibility test-
ing and detection of the Extended-spectrum beta-
Lactamase (ESBL) were ﬁrst performed by disk diffusion
and double disk synergy test and then conﬁrmed by Etest
(BioMerieux, Marcy l’Etoile, France) methods according
to the guidelines of the European Committee specialized
on Antimicrobial Susceptibility Testing (EUCAST).40
All isolates were conﬁrmed to be non-susceptible to
imipenem and/or meropenem according to the EUCAST
breakpoints as previously reported.40 As previously
reported,37 a multidisciplinary team meeting approved
the introduction of a speciﬁc antibiotic therapy in patients
who presented with at least one of the following speci-
mens positive for pathogens – peritoneal ﬂuid, peritoneal
ﬂuid cultures, drainage ﬂuid/blood or bile or tissue – dur-
ing surgical procedures according to the Infectious
Diseases Society of America and the American Society
for Microbiology.41
Candida spp. were also identiﬁed by both conventional
morphological and biochemical methods as previously
reported.37
Statistical analysis
The statistical analysis was performed using the Matrix
Laboratory (MATLAB) analytical toolbox version 2008
(MathWorks, Natick, MA, USA). Data are explicitly
presented as number and percentage for categorical vari-
ables. Continuous data expressed as the mean ± standard
deviation (SD) unless otherwise speciﬁed. The multiple
comparison chi-square tests were used to deﬁne signiﬁ-
cant differences among percentages. If the chi-square
test was signiﬁcant (p<0.05), the residual analysis with
the Z-test was performed. In the case of paired data, the
multiple comparison Cochran’s Q tests were used to
compare the differences among percentages under the
consideration of the null hypothesis that there are no
differences between the variables. When the Cochran’s
Q test was positive (p<0.05), then a minimum required
difference for a signiﬁcant difference between two pro-
portions was calculated using the Minimum Required
Differences method with Bonferroni p-value corrected
for multiple comparisons according to Sheskin (2004).
Multi-comparison tests on continuous data were per-
formed with one-way ANOVA test to evaluate signiﬁ-
cant differences among means. If the ANOVA test was
positive, the Scheffé’s method, a technique for adjusting
levels of signiﬁcance in a linear regression analysis to
Dovepress Di Carlo et al
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justify multiple comparisons, was performed for pairwise
comparison of subgroups. Also, univariate and multi-
variate linear correlation analysis was performed, where
the test on Pearson’s linear correlation coefﬁcient R was
performed with the t-Student test, under the null hypoth-
esis of Pearson’s linear correlation coefﬁcient of
R equals to zero. At this step, we deﬁned an experimen-
tal probability distribution for the patients’ survival,
therapy, disease, bacteria type, and gender. We assigned
a score 1 in the case of survival after 18 months else
zero, 1 to male and zeroed to female, 1 to therapy-
sensitive and zero with therapy resistance, 1 for positive
bacterial culture, and zero for sterile culture, and 1 for
a pancreaticobiliary disease and zero for no-disease.
To analyze the overall survival time, we categorized the
patients in four cohorts: T1, patients with death within six
months; T2, death within 12 months; T3, death within 18
months, and T3S patients alive at 18 months. Finally, we
analyzed the effect of several risk factors on survival. For this
scope, we deﬁned the dichotomous variables: Cancer_disease
(1= yes cancer: CCA, GBC, PHC, or ACA and 0 = no cancer,
ie, inﬂammatory disease: CHL, CHA, or CHP) and
Frequent_bacteria (1= most frequent: K. pneumoniae,
Pseudomonas spp or E. coli and 0 = Others). Particularly, the
Kaplan–Meier survival curves were showed for no cancer and
cancer group in Figure 2 and compared with the log-rank test;
instead, the Cox proportional-hazards regression results are
shown in Table 4 and Figure 3. All tests with p-value (p)
<0.05 were considered signiﬁcant.
Results
Patients and grouping
A total of 152 consecutive patients met our eligibility criteria
and were enrolled in the study: 53.29% males and 46.71%
females with age range of 26–93 (72±13; mean ± SD). Table 1
shows mean age, percentages by sex and isolates, pancreatic
and biliary tract diseases, and anti-infective therapy adminis-
tered in the enrolled patients divided by their follow-up control
points (T1, T2, T3, and T3S). Also, we reported the antimicro-
bials used according to antimicrobial test against bacteria iso-
lated. The statistical analysis among groups deﬁned at T1, T2,
T3, and T3S is presented in the last column of Table 1.
A multivariate analysis was performed, among all control
points for every variable considered andwhere themultivariate
analysis was positive (p<0.05) a post hoc test with pairwise
comparison was completed. In this case, only signiﬁcant
results are reported. By contrast of mean age, we found
a signiﬁcant difference (p<0.0001, one-way ANOVA); nota-
bly, there was a signiﬁcant difference between T1 patients and
T3S patients (75.56>65.15, p<0.005), ie, the dead patients
within 6months had an age signiﬁcantly greater in comparison
to survival patients at 18 months.
Microbiota identiﬁcation
For bacteria, among T1, T2, T3, and T3S, there was
a signiﬁcant difference for Alcaligenes spp (p=0.0339), the
highest frequency was localized at T2 (p=0.0354) and for
Gram-negative bacilli not identiﬁed (GNBNI) (p=0.0122)
the highest frequency was localized at T3 (p=0.0029).
In examining the pancreatic and biliary tract dis-
eases, PHC was mostly observed in dead patients at T1
(p<0.0001), CCA in deceased patients at T2 (p<0.0001),
GBC and ACA in deceased patients at T3 (both
p<0.0001), and CHL, in survival patients at T3S
(p<0.0001, p=0.0093). Regarding the therapy, there
were no signiﬁcant differences among patients who
underwent to susceptibility to antibiotics at T1, T2, T3,
and T3S.
Survival graphics, disease, and microbiota
Finally, we reported the survival rates among T1 (80/
152, 52.65%), T2 (41/80, 51.25%), and T3 (33/41,
80.49%). The survival rate was signiﬁcantly higher in
patients belonging to the T3 cohort (p=0.0042).
Particularly, the survival rates for patients with cancer
only (CCA, GBC, PHC, or ACA) among T1 (47/119,
39.50%), T2 (9/47, 19.15%), and T3 (1/9, 11.11%) and
the survival rate for patients with no cancer (CHL,
CHA, or CHP) among T1 (33/33, 100%), T2 (32/33,
96.97%), and T3 (32/32, 100%). In these cases, we
observed for cancer group a signiﬁcant differences of
survival rate among T1, T2 and T3 (p=0.0154), but at
signiﬁcant level equal to 0.05 there were no signiﬁcant
survival rate higher/lower in comparison to others, even
though at T1 the survival rate was of 39.50% greater in
comparison to others. Instead, for patients with no can-
cer, no signiﬁcant differences there were among T1, T2,
and T3 (p=0.37). Table 2 shows the results of the
statistical test into groups (ie, T1 death within six
months; T2 death within 12 months; T3 death within
18 months, and T3S alive at 18 months). We observed
that the most common bacteria in T1 were E. coli
(p<0.0001), K. pneumoniae (p=0.0215), and
P. aeruginosa (p<0.0001), while the less frequently
Di Carlo et al Dovepress
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Table 1 Characteristic of 152 studied patients divided in different groups by time of overall survival and signiﬁcant multicomparison
tests among groups: T1 death within 6 months; T2 death within 12 months; T3 death within 18 months and T3S alive at 18 months
Parameters T1 T2 T3 T3S p-value
Patients % 47.36% (72/152) 25.65% (39/152) 5.26% (8/152) 21.71% (33/152) –
<0.0001* (A)
Age (mean ± SD) 75.6±10.4 71.5±8.8 77.1±6.5 65.2±17.5 T1 vs T3S: <0.005*(Sc)
Female 43.1% (31/72) 51.3% (20/39) 25.0% (2/8) 54.5% (18/33) 0.385 (C)
Disease
<0.0001* (C)
T1: <0.0001** (Z)
T2: <0.0001*** (Z)
T3: 0.0090*** (Z)
PHC (72) 100% (72/72) 0.0% 0.0% 0.0% T3S: <0.0001*** (Z)
<0.0001* (C)
T1: 0.0001*** (Z)
T2: <0.0001** (Z)
CCA (42) 0.0% 100% (39/39) 0.0% 9.1% (3/33) T3S: 0.0351*** (Z)
<0.0001* (C)
GBC (5) 0.0% 0.0% 62.5%(5/8) 0.0% T3: <0.0001** (Z)
<0.0001* (C)
ACA (4) 0.0% 0.0% 37.5% (3/8) 3.0% (1/33) T3: <0.0001** (Z)
<0.0001* (C)
T1: 0.0042*** (Z)
T2: 0.0123*** (Z)
CHL (27) 0.0% 0.0% 0.0% 81.8% (27/33) T3S: <0.0001** (Z)
CHA (1) 0.0% 0.0% 0.0% 3.0% (1/33) 0.304 (C)
CHP (1) 0.0% 0.0% 0.0% 3.0% (1/33) 0.304 (C)
% of patients with pre-
sence of speciﬁc
pathogens isolated in
bile samples
Escherichia coli 20.8% (15/72) 28.2% (11/39) 12.5% (1/8) 24.2% (8/33) 0.726 (C)
Klebsiella pneumonia 12.5% (9/72) 2.6% (1/39) 12.5% (1/8) 15.2% (5/33) 0.295 (C)
Enterococcus spp. 0.0% 2.6% (1/39) 0.0% 3.0% (1/33) 0.516 (C)
Enterobacter spp. 1.4% (1/72) 7.7% (3/39) 0.0% 6.1% (2/33) 0.334 (C)
Citrobacter spp. 5.6% (4/72) 5.1% (2/39) 12.5% (1/8) 6.1% (2/33) 0.877 (C)
Serratia spp. 0.0% 0.0% 0.0% 3.0% (1/33) 0.304 (C)
Aeromonas spp. 1.4% (1/72) 0.0% 0.0% 0.0% 0.304 (C)
Pseudomonas aeruginosa 23.6% (17/72) 20.5% (8/39) 25.0% (2/8) 30.3% (10/33) 0.809 (C)
Stenotrophomonas spp. 5.5% (4/72) 2.6% (1/39) 0.0% 0.0% 0.454 (C)
0.0339 * (C)
Alcaligenes spp. 0.0% 10.3% (4/39) 0.0% 3.0% (1/33) T2: 0.0354 ** (Z)
Acinetobacter spp. 9.7% (7/72) 0.0% 0.0% 3.0% (1/33) 0.121 (C)
Achromobacter spp. 4.2% (3/72) 7.7% (3/39) 12.5% (1/8) 3.0% (1/33) 0.614 (C)
Brevundimonas spp. 1.4% (1/72) 5.1% (2/39) 0.0% 3.0% (1/33) 0.655 (C)
Delftia spp. 2.8% (2/72) 2.6% (1/39) 0.0% 0.0% 0.768 (C)
Elizabethkingia spp. 1.4% (1/72) 2.6% (1/39) 0.0% 0.0% 0.797 (C)
0.0122* (C)
GNBNI 4.2% (3/72) 2.6% (1/39) 25.0% (2/8) 0.0% T3: 0.0029** (Z)
Candida albicans 5.6% (4/72) 0.0% 0.0% 0.0% 0.207 (C)
(Continued)
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isolated strains included: Alcaligenes spp. (p=0.0396),
Serratia spp. (p=0.0396), and Enterococcus spp.
(p=0.0396). In T2, the most common bacteria were
E. coli (p<0.0001) and P. aeruginosa (p<0.0001), but
no one was signiﬁcantly less frequently seen in compar-
ison to others. In T3, there were no bacteria isolated in
comparison to others. In T3S, the most common bacteria
were similar to those found in T1, while there were no
bacteria signiﬁcantly less frequent in comparison to
others.
Therapy and general drug resistance
We observed that E. coli, K. pneumoniae, and
P. aeruginosa showed a high percentage of resistance to
third-generation cephalosporins (3GCs), aminoglycosides
class, and quinolone group, especially to levoﬂoxacin in
cohort one and two were the several numbers of enrolled
pts are enrolled presented and/or alive.
On the other hand, the analysis of susceptibility test showed
thatE. coli, K. pneumoniae, andP. aeruginosa had a percentage
of sensibility to adopted carbapenem of about 70%.
Pancreatic/biliary tract diseases,
microbiota, drugs, and correlation
analysis
Regarding the pancreatic and biliary tract diseases, PHC
was the most frequent disease in T1 (p<0.0001), CCA in
T2 (p<0.0001), while GBC (p<0.0001) and ACA
(p=0.0139) were more often seen in T3. At T3S, the most
frequent pancreatic and biliary tract disease was CHL
(p<0.0001), while less frequent diseases included PHC
and GBC (p=0.0299). In other words, the PHC had the
highest impact on dead patients within six months. About
the antibiotic therapy, we observed that the most frequent
treatments in T1 were meropenem (p<0.005) and imipe-
nem (p<0.005), while the less commonly occurring ther-
apy was levoﬂoxacin (p<0.005). In T2, we more often
encountered meropenem (p<0.005) and ertapenem
(p<0.005), while the fewer common antibiotics were
ciproﬂoxacin, levoﬂoxacin, and 3CGs. In T3, there was
no therapy, which was signiﬁcant in any category.
Conversely, in T3S, meropenem was the most frequent
therapy identiﬁed (p<0.005). Fewer standard treatments
Table 1 (Continued).
Parameters T1 T2 T3 T3S p-value
% of Patients where
the pathogens isolated
in bile were sensible
(S) to the speciﬁc
therapy
Meropenem 79.2% (57/72) 74.4% (29/39) 75.0% (6/8) 75.8% (25/33) 0.98 (C)
Imipenem 80.6% (58/72) 71.8% (28/39) 62.5% (5/8) 72.7% (24/33) 0.54 (C)
Ertapenem 75.0% (54/72) 76.9% (30/39) 75.0% (6/8) 72.7% (24/33) 0.98 (C)
3GCs plus MT 63.9% (46/72) 51.3% (20/39) 50.0% (4/8) 42.4% (14/33) 0.20 (C)
Aminoglycosides 47.2% (34/72) 38.5% (15/39) 50.0% (4/8) 36.4% (12/33) 0.66 (C)
Ciproﬂoxacin 58.3% (42/72) 35.9% (14/39) 37.5% (3/8) 39.4% (13/33) 0.08 (C)
Levoﬂoxacin 37.5% (27/72) 18.0% (7/39) 37.5% (3/8) 33.3% (11/33) 0.20 (C)
3GCs 43.1% (31/72) 25.6% (10/39) 25.0% (2/8) 30.3% (10/33) 0.24 (C)
Total survival rate 52.6% (80/152) 51.3% (41/80) 80.5% (33/41) 33 0.0033 * (C)
T3: 0.0042 *** (Z)
Survival rate in cancer
group only (CCA, GBC,
PHC or ACA)
39.50% (47/119) (9/47)19.15% (1/9) 11.11% 1 0.0154 * (C)
No localized signiﬁcant results
at signiﬁcant level α =0.05
Survival rate in no cancer
group only
(CHL, CHA or CHP)
(33/33)100% (32/33) 96.97% (32/32)100% 32 0.37 (C)
Notes: T1 = death within 6 months, T2 = death within 12 months; T3 = death within 18 months; T3S = patients survival at T3. *Signiﬁcant test; **Signiﬁcant more frequent;
***Signiﬁcant less frequent.
Abbreviations: GNBNI, gram negative bacilli not identiﬁed; N, no response; R, resistant; S, sensible; 3GCs, 3rd generation cephalosporin; MT, metronidazole; CCA,
cholangiocarcinoma; PHC, carcinoma of the head of the pancreas; ACA, ampullary carcinoma; GBC, gallbladder carcinoma; CHL, cholelithiasis; CHA, cholangitis; CHP,
chronic pancreatitis; A, one way ANOVA test; Sc, Schaffè test for pairwise comparison; C, multicomparison chi-square test; Z, Z-test.
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used in T3S were aminoglycosides, levoﬂoxacin, and 3GCs
(p<0.005).
Table 3 shows univariate and multivariate linear correla-
tion analysis considering as dependence variable: survival
patients and independence variables: age, gender, most fre-
quently: isolated strains (E coli, K pnumoniae, P. aeruginosa),
underlying diseases (PHC, CCA, ACA, GBC, and CHL), and
carbapenem class (meropenem, imipenem, and ertapenem).
By multivariate analysis, the negative signiﬁcant predic-
tors of survival were: PHC (p<0.0001), CCA (p<0.0001),
ACA (p<0.0001), GBC (p<0.0001), and CHL (p=0.0040).
There were no signiﬁcant positive predictors. In other
Table 2 Multicomparison tests among percentages into groups: T1 death within 6 months; T2 death within 12 months; T3 death within
18 months and T3S alive at 18 months
Parameters T1 T2 T3 T3S
Bacteria <0.0001 * (C) <0.0001 * (C) 0.34 (C) <0.0001 * (C)
Escherichia coli <0.0001 ** (Z) <0.0001 ** (Z) − <0.0001 ** (Z)
Klebsiella pneumoniae 0.0215 ** (Z) − − 0.0408 ** (Z)
Enterococcus spp 0.0396 *** (Z) − − −
Enterobacter spp − − − −
Citrobacter spp − − − −
Serratia spp 0.0396 *** (Z) − − −
Aeromonas spp − − − −
Pseudomonas aeruginosa <0.0001 ** (Z) <0.0001 ** (Z) − −
Stenotrophomonas spp − − − <0.0001 ** (Z)
Alcaligenes spp 0.0396 *** (Z) − − −
Acinetobacter spp − − − −
Achromobacter spp − − − −
Brevundimonas spp − − − −
Delftia spp − − − −
Elizabethkingia spp − − − −
GNBNI − − − −
Disease <0.0001 * (C) <0.0001 * (C) <0.0001 * (C) <0.0001 * (C)
PHC <0.0001 ** (Z) 0.0165 *** (Z) − 0.0299 *** (Z)
CCA 0.0073 *** (Z) <0.0001 ** (Z) − −
GBC 0.0073 *** (Z) 0.0165 *** (Z) <0.0001 ** (Z) 0.0299 *** (Z)
ACA 0.0073 *** (Z) 0.0165 *** (Z) 0.0139 ** (Z) −
CHL 0.0073 *** (Z) 0.0165 *** (Z) − <0.0001 ** (Z)
CHA 0.0073 *** (Z) 0.0165 *** (Z) − −
CHP 0.0073 *** (Z) 0.0165 *** (Z) − −
The most and less frequent
therapy used in patients with
bile disease
<0.0001 * (Q) test <0.0001 * (Q) 0.10 (Q) <0.0001 * (Q)
Meropenem <0.005 ** (Sh) <0.005 ** (Sh) − <0.005 ** (Sh)
Imipenem <0.005 ** (Sh) − − −
Ertapenem − <0.005 ** (Sh) − −
3GCs plus MT − − − −
Aminoglycosides − − − <0.005 *** (Sh)
Ciproﬂoxacin − <0.005 *** (Sh) − −
Levoﬂoxacin <0.005 *** (Sh) <0.005 *** (Sh) − <0.005 *** (Sh)
3GCs − <0.005 *** (Sh) − <0.005 *** (Sh)
Notes: *Signiﬁcant test; **Signiﬁcant more frequent; ***Signiﬁcant less frequent; T1 =6 months, T2 =12 months, and T3 =18 months; T3S = patients survival at T3.
Abbreviations: Q, multicomparison Cochran’s Q test; (Sh) Sheskin’s procedure for signiﬁcant difference between two proportions; C, multicomparison chi-square test; Z,
Z-test; GNBNI, Gram negative bacilli not identiﬁed; N, no response; R, resistant; S, Bacteria sensible to the therapy; NT, no therapy; 3GCs, 3rd generation cephalosporin;
MT, metronidazole; CCA, cholangiocarcinoma; PHC, carcinoma of the head of the pancreas; ACA, ampullary carcinoma; GBC, gallbladder carcinoma; CHL, cholelithiasis;
CHA, cholangitis; CHP, chronic pancreatitis.
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Table 3 Univariate and multivariate linear correlation analysis on the most frequent bacteria and disease, age, gender, and survival
patients
Linear correlation analysis Univariate analysis Multivariate analysis
Parameters R (p-value) Rpartial; p-value
Multiple linear correlation coefﬁcient =1.0
Survival patients/PHC −0.45 (<0.0001) * Rpartial= −0.99; p-value <0.0001 *
Survival patients/CCA −0.22 (0.0062) * Rpartial = −0.98; p-value <0.0001 *
Survival patients/ACA 0.33 (<0.0001) * Rpartial = −0.90; p-value <0.0001 *
Survival patients/GBC −0.55 (<0.0001) * Rpartial = −0.98; p-value <0.0001 *
Survival patients/CHL 0.43 (<0.0001) * Rpartial = −0.24; p-value =0.0040 *
Survival patients/E. coli −0.21 (0.0088) * Rpartial = 0.04; p-value =0.68
Survival patients/K. pneumoniae 0.16 (0.0495) * Rpartial = 0.05; p-value =0.58
Survival patients/Pseudomonas aeruginosa 0.23 (0.0038) * Rpartial = −0.07; p-value =0.45
Survival patients/Meropenem −0.20 (0.0157) * Rpartial = 0.05; p-value =0.59
Survival patients/Imipenem 0.08 (0.31) Rpartial = −0.02; p-value =0.84
Survival patients/Ertapenem −0.13 (0.11) Rpartial = −0.08; p-value =0.38
Survival patients/Age −0.10 (0.20) Rpartial = −0.16; p-value =0.06
Survival patients/Gender −0.09 (0.25) Rpartial = −0.11; p-value =0.10
Multiple linear correlation coefﬁcient =0.63
PHC/E. coli 0.52 (<0.0001) * Rpartial =0.29; p-value =0.0003 *
PHC/K. pneumoniae −0.46 (<0.0001) * Rpartial =−0.27; p-value =0.0008 *
PHC/Pseudomonas aeruginosa 0.13 (0.12) Rpartial =0.058; p-value =0.48
Multiple linear correlation coefﬁcient =0.59
CCA/E. coli −0.35 (<0.0001) * Rpartial =−0.42; p-value <0.0001 *
CCA/K. pneumoniae 0.42 (<0.0001) * Rpartial =−0.09; p-value =0.26
CCA/Pseudomonas aeruginosa −0.36 (<0.0001) * Rpartial =−0.43; p-value <0.0001 *
Multiple linear correlation coefﬁcient =0.16
GBC/E. coli −0.12 (0.16) Rpartial =0.01; p-value =0.93
GBC/K. pneumoniae 0.13 (0.11) Rpartial =0.12; p-value =0.16
GBC/Pseudomonas aeruginosa 0.03 (0.70) Rpartial =0.08; p-value =0.32
Multiple linear correlation coefﬁcient =0.16
ACA/E. coli −0.08 (0.31) Rpartial =0.06; p-value =0.44
ACA/K. pneumoniae 0.25 (0.0017) * Rpartial =0.20; p-value =0.0131 *
ACA/Pseudomonas aeruginosa −0.12 (0.15) Rpartial =0.04; p-value =0.65
Multiple linear correlation coefﬁcient =0.52
CHL/E. coli −0.21 (0.0099) * Rpartial =−0.22; p-value =0.0083 *
CHL/K. pneumoniae 0.43 (<0.0001) * Rpartial =0.06; p-value =0.45
CHL/Pseudomonas aeruginosa −0.40 (<0.0001) * Rpartial =−0.33; p-value <0.0001 *
Multiple linear correlation coefﬁcient =0.59
E coli/Meropenem 0.36 (<0.0001) * Rpartial =0.32; p-value =0.0001 *
E coli/Imipenem 0.51 (<0.0001) * Rpartial =0.49; p-value <0.0001 *
E coli/Ertapenem 0.15 (0.06) Rpartial = −0.30; p-value =0.0002 *
Multiple linear correlation coefﬁcient =0.76
K. pneumoniae/Meropenem −0.24 (0.0027) * Rpartial =0.10; p-value =0.24
K. pneumoniae/Imipenem −0.75 (<0.0001) * Rpartial =−0.72; p-value <0.0001 *
K. pneumoniae/Ertapenem −0.33 (<0.0001) * Rpartial =0.02; p-value =0.65
Multiple linear correlation coefﬁcient =0.56
Pseudomonas aeruginosa/Meropenem 0.029 (0.72) Rpartial =−0.35; p-value <0.0001 *
Pseudomonas aeruginosa/Imipenem 0.45 (<0.0001) * Rpartial =0.40; p-value <0.0001 *
Pseudomonas aeruginosa/Ertapenem 0.35 (<0.0001) * Rpartial =0.33; p-value <0.0001 *
Notes: *signiﬁcant test; R = Pearson’s linear correlation coefﬁcient; Rpartial= the partial correlation coefﬁcient is the coefﬁcient of correlation of the variable with the
dependent variable, adjusted for the effect of the other variables in the mode
Abbreviations: CCA, cholangiocarcinoma; PHC, carcinoma of the head of the pancreas; ACA, ampullary carcinoma; GBC, gallbladder carcinoma; CHL, cholelithiasis.
Di Carlo et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:121520
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
16
3.
72
.1
60
 o
n 
24
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
words, the presence of PHC, CCA, ACA, GBC, and CHL
implicated a decreasing of survival.
In univariate analysis, the survival was negatively corre-
lated to PHC (p<0.0001), CCA (p<0.0001), GBC
(p<0.0001), E. coli (p=0.0088), and meropenem
(p=0.0157). Conversely, the survival was positively corre-
lated to ACA (p<0.0001), CHL (p<0.0001), K. pneumoniae
(p=0.0495), and P. aeruginosa (p=0.0038). Considering
each variable individually, we found that the presence of
PHC, CCA, GBC, E. Coli, and meropenem was connected
to patients with low survival. On the other hand, ACA, CHL,
K. pneumoniae, and P. aeruginosa were connected with
patients who survived more in comparison to others.
Considering additional analyses, we observed that in
univariate and multivariate analysis E. coli was
a signiﬁcant positive predictor of PHC, ie, the presence
of E. coli is associated with PHC. In both univariate and
multivariate analysis, K. pneumoniae was a signiﬁcant
negative predictor of PHC, ie, the presence of
K. pneumoniae does not implicate the presence of PHC.
In the univariate and multivariate analysis, E. coli and
P. aeruginosa were signiﬁcant negative predictors of CCA. In
other words, E. coli or P. aeruginosa. suggests the absence of
CCA. Moreover, only in univariate analysis K. pneumoniae
was positively correlated to CCA, and K. pneumoniae impli-
cates CCA. About GBC, there were no signiﬁcant correla-
tions with E. coli, K. pneumoniae, and P. aeruginosa.
In the univariate and multivariate analysis,
K. pneumoniae was a signiﬁcant positive predictor of
ACA, ie, the presence of K. pneumoniae implicates the
diagnosis of ACA. In the univariate and multivariate
analysis, E. coli and P. aeruginosa were signiﬁcant
negative predictors of gallstone disease, ie, the presence
of E. coli or P. aeruginosa may implicate the absence
of CHL.
In univariate analysis alone, K. pneumoniae was posi-
tively correlated to CHL, ie, the presence of
K. pneumoniae would suggest CHL.
Figure 1 summarizes all signiﬁcant linear correlations
described in Table 3. Particularly in Figure 1, the depen-
dence variable: survival patients was associated with the
vertical axis. The independent variables: PHC, CCA,
ACA, GBC, CHL, E coli, K. pneumoniae, P. aeruginosa,
meropenem, were located on the horizontal axis.
Regarding bacteria, the scatter plot showed a negative
correlation between E. coli and survival variable.
Moreover, the scatter plot showed a negative association
between CCA and PHC and survival.
By Kaplan–Meier survival curves comparison, among
patients with cancer (CCA, GBC, PHC, or ACA) and no
cancer (CHL, CHA, or CHP), we conﬁrmed a signiﬁcant
difference (p-value <0.0001, log-rank test, Figure 2).
Finally, we considered the Cox proportional hazard
regression to evaluate the effect of several risk factors on
Table 4 Cox proportional-hazards regression
Covariates Percentages or mean ± SD HR 95% CI p-value
Age 72.3±12.6 1.0 0.99–1.03 0.48
Gender
● Male
● Female
53.3 (81/152)
46.7 (71/152)
1.0 0.67–1.40 0.87
Therapy
● % patients therapy Sensible
● % patients therapy Resistant
94.7 (144/152)
5.3 (8/152)
0.6 0.26–1.37 0.22
Frequent bacteria
● K. Pneumoniae + Pseudomonas aeruginosa+ E. coli
● Others
57.9 (88/152)
42.1 (64/152)
1.1 0.74–1.53 0.74
Disease type
● % patients with cancer: CCA, GBC, PHC or ACA
● % patients with inﬂammatory disease CHL, CHA or CHP
78.3 (119/152)
21.7 (33/152)
73.6 10.1–537.5 <0.0001 *
Note: *Signiﬁcant test.
Abbreviations: HR, hazard ratio(s); CCA, Cholangiocarcinoma; PHC, carcinoma of the head of the pancreas; ACA, ampullary carcinoma; GBC, gallbladder carcinoma;
CHL, cholelithiasis; CHA, cholangitis; CHP, chronic pancreatitis HR, hazards ratio; CI, conﬁdence interval; SD, standard deviation.
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survival. The risk factors or covariates studied were repre-
sented by Age, Gender, Bacteria, and Disease variables. For
this scope, two models were considered – the null model:
−2ln(L0), where L0 is the likelihood to obtain the observa-
tions if the independent variables did not affect the outcome,
and the full model: −2ln(L0), where L0 is the likelihood of
achieving the views with all independent variables incorpo-
rated in the model. The difference between these two yields
was estimated with the chi-square test, to deﬁne howwell the
independent variables may affect the outcome or dependent
variable. By chi-square test, the p-value <0.0001, ie, there
was evidence that at least one of the independent variables or
covariates contributes to the prediction of the outcome. By
this investigation, it results that only the presence of cancer
provides a signiﬁcant contribution to survival time in com-
parison to other covariates considered, as shown by Cox
proportional hazard regression analysis (Figure 3 and
Table 4).
Discussion
Bacteria and candida colonizing pancreatic and biliary tract
tissues may be involved in chronic inﬂammation and cancer
evolution.37 In the twenty-ﬁrst century, scientists started
hypothesizing that chronic inﬂammation caused by persistent
bacterial infections might lead to carcinogenesis and bacter-
ial toxins and secondary metabolites produced by the chronic
bacterial infection might induce carcinogenesis, and some
mechanisms of cholangiocarcinogenesis have been
delineated.9,10,42
Emerging studies on pancreatic, biliary tract, and gall-
bladder disease have been identiﬁed as the signiﬁcant
pathogens implicated in inﬂammatory and tumor micro-
environment (TME).43,44
In comparison to these studies, our study analyzed two
proper further investigations: we analyzed both the survi-
val rate of different cohorts of pats about pathogens iden-
tiﬁed during bile culture after the ﬁrst diagnosis of BPS,
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Figure 1 Signiﬁcant Linear correlations between independent variables: pancreas head carcinoma, cholangiocellular carcinoma, ampullary carcinoma, gallbladder carcinoma,
gallbladder stone disease, E. coli, K pneumoniae, Pseudomonas spp., Meropenem and the dependent variable of survival of the patients. Also, the asterisks represented a pair of
values (independence variable, dependence variable) and the red line indicated the best linear correlation model of the scatter plot points.
Abbreviations: CCA, cholangiocarcinoma; PHC, carcinoma of the head of the pancreas; ACA, ampullary carcinoma; GBC, gallbladder carcinoma; CHL, cholelithiasis.
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Kaplan-Meier survival curves comparison
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Figure 2 The Kaplan–Meier curves comparison with log-rank test, considering the dichotomous variable: Cancer_disease, used to deﬁne two groups: group with cancer and
group without cancer.
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Figure 3 Cox proportional – hazard regression analysis. In the graph, a single survival curve at a mean of all covariates in the model is shown. The survival curve represents
the probability (Y-axis) of surviving a given length of time (X-axis).
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and we examined the survival rate regarding anti-infective
therapy according to results of antimicrobial tests.
Regarding the ﬁrst point, we found that E. coli,
P. aeruginosa, and K. pneumoniae are the leading bacteria
isolated.
When we analyze these three Gram-negative pathogens
each examined individually about the following variables:
survival time (T1, T2, T3) and pathology of the biliopan-
creatic tract, the results obtained are different:
E. coli, P. aeruginosa, and K. pneumoniae were the most
signiﬁcant pathogens isolated in patients’ death within six
months from diagnosis of PBD and again E. coli and
P. aeruginosa were prevalent in patients’ death within the
ﬁrst year. Regarding underlying diseases, in general, the
presence of E. coli, P. aeruginosa, and K. pneumoniae
was statistically signiﬁcant identiﬁed in the cancer popula-
tion, and their presence reduces survival time.
In particular, E. coli seems to be the bacterium that
most correlates with a reduction in survival and in uni-
variate and multivariate analysis E. coli was a signiﬁcant
positive predictor of PHC.
These ﬁndings are in harmony with Costi et al who
reported E. coli in the bile being signiﬁcantly related to
poor outcome in pancreaticoduodenectomies.45 A few
years ago, we described an outbreak of colonization by
ESBL-producing E. coli (ESBL-E. coli) in intensive care
units.35,39,46–48 A variety of E. coli, called as ESBL-
producing E. coli (ESBLEC), is currently considered
a signiﬁcant cause of bacteremia in cancer patients.49,50
These strains showed some microbiological determinants,
including virulence factors, involving adhesion to and
invasion of host cells, iron availability, toxic effects on
host cells, or protecting factors against the host’s immune
system.39,51 They are recognized as the etiologic agents of
hospital infections mainly through the urinary tract.
Moreover, they are playing a tremendous role in the ﬁeld
of transmission through the food chain, and therefore they
can colonize healthy subjects and could be responsible for
severe infections as soon as the decay of the immune
system of elderly patients.52
Recently, in our geographical area, we have investigated
the presence of E. coli ST131 in food animals.53,54 E. coli
ST131 is increasing rapidly worldwide and shows resis-
tance to ﬂuoroquinolones. By antimicrobial susceptibility
analysis, the percentage of sensibility to a ﬂuoroquinolone
was low, while most of our E. coli strains were susceptible
only to carbapenem class. Moreover, analyzing the correla-
tions described in Table 3 where E coli compared to
K. pneumoniae and P. aeruginosa has a signiﬁcant negative
association with survival, this means that an increase of
E. coli in bile leads to a decrease in survival, while this is
not found for K. pneumoniae and P. aeruginosa. This result
could be helpful in the management of pancreatic tract
disorders. For example, knowing that E. coli is more inci-
sive on the reduction of survival, other antibiotics could be
used, especially in patients with PHC where the probability
of E. coli was present in bile was higher than other bacteria.
Among the relationship between microorganisms and
cancer of pancreatic and biliary system, we found that
K. pneumoniae is the bacterium with a reduction in survi-
val in CCA patients.
The isolation of pathogens has not always shown
a negative correlation with the survival because in non-
carcinomatous pathologies especially gallstone disease the
ﬁndings of above-mentioned gram-negative bacilli as
E. coli, P. aeruginosa, and K. pneumoniae had a negative
predictor of the biliary calculi.
Therefore, we could conﬁrm that it is the TME that
inﬂuences the signiﬁcance of the ﬁnding of some microor-
ganisms. In the future, it would be interesting to investigate
the protective role of Alcaligenes spp. in the gut microbiome.
Regarding the survival and anti-infective treatment, we
found that E. coli, K. pneumoniae, and P. aeruginosa showed
a high percentage of resistant to 3CGS, aminoglycosides
class, and quinolone group, especially to levoﬂoxacin. On
the other hand, the analysis of susceptibility test showed that
E. coli, K. pneumoniae, and P. aeruginosa had a percentage
of sensibility to adopted carbapenem (meropenem, imipe-
nem, and ertapenem) more than 70% of all isolated strains.
In fact, the prescription of meropenem due to the iso-
lation of pathogens resistant to other class of antibiotics
seems to be associated with a decrease in survival. The
scatter plot for meropenem shows a negative linear corre-
lation between survival and antibiotic, ie, if meropenem
use/dosage increases, the survival decreases. On the other
hand, the isolation of pathogens sensible to carbapenem
class alone may be contributing to the emerging of parti-
cular multi-drug-resistant microbiota.
Moreover, in our study, K. pneumoniae was negatively
associated with meropenem, imipenem, and ertapenem
showing a decrease of sensitivity to the carbapenem class
conﬁrming two previously described cases.36
Resistant pathogens are increasingly reported in cancer
patients and may be associated with cancer screening tests.
The widespread use of these drugs can lead to the emer-
gence of metallo-beta-lactamase strains as the authors have
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previously reported in NICU setting.55 Infectious disease
consultants in an emergency setting often must prescribe an
immediate antimicrobial therapy, which is based on co-
morbidities such as type 2 diabetes mellitus, obesity,
chronic liver disease, alcoholism. Mono- or combined anti-
microbial therapy needs to be chosen considering the most
favorable pharmacokinetic/pharmacodynamic proﬁles, and
tissue penetration against the isolated bacteria, as well as the
acquisition and interpretation of the hospital ecology.33,34
The Cox proportional-hazard regression indicates that
only the presence of cancer disease per se provides
a signiﬁcant contribution to survival time in comparison
to other covariates.
In conclusions, our study suggests that some strains
isolate in bile samples may be considered within the group
of risk factors in carcinogenesis and/or progression of
hepato-biliary malignancy.
Moreover, the knowledge of bile microbiota and suscept-
ibility test results highlight the necessity to consider the
multidisciplinary management of patients with inﬂammation
and cancer of pancreatic and biliary tract disease PBD. The
ﬁnding that pathogens isolated in gut microbiota belong to
the same class of pathogens responsible for sepsis in cancer
patients may indicate that dysbiosis favors the production of
genotoxins and metabolites inducing the dysregulation of the
immune response, which may favor carcinogenesis.
The primary limitation may entail the local event (single-
center). A multicentric investigation involving several geo-
graphic areas may be warranted to address public health
policies. This aspect may be important because the coloniza-
tion by resistant germs could signiﬁcantly inﬂuence the
future medical approach.56 The development of inﬂamma-
tory bowel disease that may be associated with biliary dis-
eases highlights the qualitative and quantitative disorders of
the microbiota of the intestine (dysbiosis). Increasing evi-
dence indicates that dysbiosis favors indeed the production of
genotoxins and metabolites that induce dysregulation of the
immune response of the most closely associated with
carcinogenesis.57 Some microorganisms occur in speciﬁc
pancreatic and biliary diseases, and our data may be vital in
addressing the anti-infective therapy in patients harboring
PBD neoplasms.
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